First-line treatment with dual-targeted therapies and chemotherapy doubles overall survival in patients with BRAF-mutated metastatic colorectal cancer - EurekAlert!
ASCO: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer - EurekAlert!
Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer
Complete response to encorafenib + binimetinib in BRAF V600E-mutant tumor - EurekAlert
